期刊
DRUG DISCOVERY TODAY
卷 27, 期 7, 页码 1945-1953出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2022.02.013
关键词
Nucleoside analogues; Antiviral therapy; (Re)emerging RNA viruses; Broad-spectrum antiviral agents; RNA-dependent RNA polymerase (RdRp)
Nucleoside and nucleotide analogs are important drugs for antiviral treatments, but there are currently no available vaccines or small antivirals for (re)emerging RNA viruses. Thus, the recently developed ribonucleoside analogs have the potential to lead to the discovery of new antiviral nucleosides.
With several US Food and Drug Administration (FDA)-approved drugs and high barriers to resistance, nucleoside and nucleotide analogs remain the cornerstone of antiviral therapies for not only herpesviruses, but also HIV and hepatitis viruses (B and C); however, with the exception of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for which vaccines have been developed at unprecedented speed, there are no vaccines or small antivirals yet available for (re)emerging viruses, which are primarily RNA viruses. Thus, herein, we present an overview of ribonucleoside analogs recently developed and acting as inhibitors of the viral RNA-dependent RNA polymerase (RdRp). They are new lead structures that will be exploited for the discovery of new antiviral nucleosides.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据